Submissions for variant NM_000059.3(BRCA2):c.6886A>C (p.Ile2296Leu) (rs576279166)

Minimum review status:		Collection method:
Minimum conflict level:
		ClinVar version:

Total submissions: 9

Download table as spreadsheet

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Ambry Genetics	RCV000132216	SCV000187298	uncertain significance	Hereditary cancer-predisposing syndrome	2017-12-14	criteria provided, single submitter	clinical testing	Lines of evidence used in support of classification: Insufficient or conflicting evidence,In silico models in agreement (benign)
Color	RCV000132216	SCV000910979	likely benign	Hereditary cancer-predisposing syndrome	2016-11-04	criteria provided, single submitter	clinical testing
Counsyl	RCV000410842	SCV000488288	uncertain significance	Breast-ovarian cancer, familial 2	2016-02-12	criteria provided, single submitter	clinical testing
GeneDx	RCV000479638	SCV000571484	likely benign	not specified	2017-11-21	criteria provided, single submitter	clinical testing	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Illumina Clinical Services Laboratory,Illumina	RCV000353391	SCV000383748	likely benign	Fanconi anemia	2016-06-14	criteria provided, single submitter	clinical testing
Illumina Clinical Services Laboratory,Illumina	RCV000203848	SCV000383749	likely benign	Hereditary breast and ovarian cancer syndrome	2016-06-14	criteria provided, single submitter	clinical testing
Integrated Genetics/Laboratory Corporation of America	RCV000479638	SCV000918806	likely benign	not specified	2018-01-29	criteria provided, single submitter	clinical testing	Variant summary: BRCA2 c.6886A>C (p.Ile2296Leu) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function and the variant is located outside of any known domain or repeat. The observed variant frequency within South Asian control individuals in the gnomAD database (42/30676 chrs) is approximately 1.87 fold of the estimated maximal expected allele frequency for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer phenotype (0.00075), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. To our knowledge, no occurrence of c.6886A>C in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant as VUS/Likely Benign. Based on the evidence outlined above, the variant was classified as likely benign.
Invitae	RCV000203848	SCV000261976	likely benign	Hereditary breast and ovarian cancer syndrome	2018-01-03	criteria provided, single submitter	clinical testing
True Health Diagnostics	RCV000132216	SCV000787946	uncertain significance	Hereditary cancer-predisposing syndrome	2018-02-05	no assertion criteria provided	clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.